Fluid conduit assembly with air venting features

Information

  • Patent Grant
  • 9833564
  • Patent Number
    9,833,564
  • Date Filed
    Tuesday, November 25, 2014
    9 years ago
  • Date Issued
    Tuesday, December 5, 2017
    6 years ago
Abstract
A fluid conduit assembly for delivery of a medication fluid, and an associated fluid delivery system, are disclosed here. The fluid conduit assembly includes a trapping chamber having an interior volume to receive the medication fluid. The fluid conduit assembly also includes an inlet in fluid communication with the interior volume, a first outlet arrangement for the trapping chamber, and a second outlet arrangement for the trapping chamber. The first outlet arrangement accommodates flow of liquid from the interior volume, while inhibiting flow of gas from the interior volume. The second outlet arrangement accommodates flow of gas from the interior volume, while inhibiting flow of liquid from the interior volume.
Description
TECHNICAL FIELD

Embodiments of the subject matter described herein relate generally to fluid infusion devices for delivering a medication fluid to the body of a user. More particularly, embodiments of the subject matter relate to the use of a trapping chamber in the medication fluid flow path.


BACKGROUND

Certain diseases or conditions may be treated, according to modern medical techniques, by delivering a medication fluid or other substance to the body of a patient, either in a continuous manner or at particular times or time intervals within an overall time period. For example, diabetes is commonly treated by delivering defined amounts of insulin to the patient at appropriate times. Some common modes of providing insulin therapy to a patient include delivery of insulin through manually operated syringes and insulin pens. Other modern systems employ programmable fluid infusion devices (e.g., continuous insulin infusion devices such as insulin pumps) to deliver controlled amounts of insulin or other drugs to a patient.


A fluid infusion device suitable for use as an insulin pump may be realized as an external device or an implantable device, which is surgically implanted into the body of the patient. External fluid infusion devices include devices designed for use in a generally stationary location (for example, in a hospital or clinic), and devices configured for ambulatory or portable use (to be carried by a patient). External fluid infusion devices may establish a fluid flow path from a fluid reservoir to the patient via, for example, a suitable hollow tubing. The hollow tubing may be connected to a hollow fluid delivery needle that is designed to pierce the patient's skin to deliver an infusion fluid to the body. Alternatively, the hollow tubing may be connected directly to the patient's body through a cannula or set of micro-needles.


It is desirable to reduce the amount of air bubbles in a medication fluid before delivering the fluid to the patient. Small bubbles may be introduced into the medication fluid during a reservoir filling operation, for example, when the fluid reservoir is filled from a vial using a syringe. Bubbles can also be generated during temperature or altitude changes. Although patients are instructed to eliminate air from a filled reservoir, some micro bubbles may remain.


Accordingly, it is desirable to have an assembly, system, or component that is designed to mitigate the effects of air bubbles within a medication fluid flow path. Furthermore, other desirable features and characteristics will become apparent from the subsequent detailed description and the appended claims, taken in conjunction with the accompanying drawings and the foregoing technical field and background.


BRIEF SUMMARY

Disclosed herein is a fluid conduit assembly for delivery of a medication fluid. An exemplary embodiment of the fluid conduit assembly includes a trapping chamber having an interior volume to receive the medication fluid. The fluid conduit assembly also includes an inlet in fluid communication with the interior volume, a first outlet arrangement for the trapping chamber, and a second outlet arrangement for the trapping chamber. The first outlet arrangement accommodates flow of liquid from the interior volume and inhibits flow of gas from the interior volume. The second outlet arrangement accommodates flow of gas from the interior volume and inhibits flow of liquid from the interior volume.


Yet another embodiment of a fluid conduit assembly presented here includes a trapping chamber having an interior volume to receive fluid, an inlet in fluid communication with the interior volume, a delivery hole formed in a wall of the trapping chamber, a first membrane covering the delivery hole, a vent hole, and a second membrane covering the vent hole. The first membrane has hydrophilic properties to accommodate flow of liquid from the interior volume through the delivery hole while inhibiting flow of gas from the interior volume through the delivery hole. The second membrane has hydrophobic properties to accommodate flow of gas from the interior volume through the vent hole while inhibiting flow of liquid from the interior volume through the vent hole.


Another embodiment of a fluid delivery system is also presented here. The system includes a fluid infusion pump and a fluid conduit assembly coupled to the fluid infusion pump. The fluid conduit assembly includes a trapping chamber having an interior volume to receive fluid from a fluid source, a liquid outlet arrangement, and a gas outlet arrangement. The liquid outlet arrangement allows liquid to flow from the interior volume to a fluid delivery conduit while inhibiting flow of gas from the interior volume to the fluid delivery conduit. The gas outlet arrangement allows gas to exit the interior volume while inhibiting flow of liquid from the interior volume.


This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures.



FIG. 1 is a simplified block diagram representation of an embodiment of a fluid delivery system;



FIG. 2 is a plan view of an exemplary embodiment of a fluid delivery system that includes a fluid infusion device and an infusion set;



FIG. 3 is a perspective view of an exemplary embodiment of a fluid delivery system that includes a fluid infusion device designed to be affixed to the skin of the user;



FIG. 4 is a simplified block diagram representation of an embodiment of a trapping chamber suitable for use in a fluid conduit assembly;



FIG. 5 is a perspective view of an embodiment of a fluid conduit assembly that is realized as a cap for a fluid reservoir;



FIG. 6 is a cross-sectional view of a portion of a fluid conduit assembly having a trapping chamber; and



FIG. 7 is a top view of certain features of the fluid conduit assembly shown in FIG. 6.





DETAILED DESCRIPTION

The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.


The subject matter described here relates to certain assemblies, components, and features of a fluid infusion system of the type used to treat a medical condition of a patient. The fluid infusion system is used for infusing a medication fluid into the body of a user. The non-limiting examples described below relate to a medical device used to treat diabetes (more specifically, an insulin pump), although embodiments of the disclosed subject matter are not so limited. Accordingly, the medication fluid is insulin in certain embodiments. In alternative embodiments, however, many other fluids may be administered through infusion such as, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. Moreover, the gas trapping filter described below could be utilized in the context of other fluid delivery systems if so desired.


For the sake of brevity, conventional features and technologies related to infusion system operation, insulin pump and/or infusion set operation, and other functional aspects of the fluid infusion system (and the individual operating components of the system) may not be described in detail here. Examples of infusion pumps and/or related pump drive systems used to administer insulin and other medications may be of the type described in, but not limited to, U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,351; 6,659,980; 6,752,787; 6,817,990; 6,932,584; and 7,621,893; which are herein incorporated by reference.



FIG. 1 is a simplified block diagram representation of an embodiment of a fluid delivery system 100, which can be utilized to administer a medication fluid such as insulin to a patient. The fluid delivery system 100 includes a fluid infusion device 102 (e.g., an infusion pump) and a fluid conduit assembly 104 that is coupled to, integrated with, or otherwise associated with the fluid infusion device 102. The fluid infusion device 102 includes a fluid reservoir 106 or an equivalent supply of the medication fluid to be administered. The fluid infusion device 102 is operated in a controlled manner to deliver the medication fluid to the user via the fluid conduit assembly 104. Although not depicted in FIG. 1, the fluid conduit assembly 104 and/or the fluid reservoir 106 can be provided with a trapping chamber that receives the medication fluid and allows the liquid component of the medication fluid to flow downstream while venting gas/air that may be present in the medication fluid. In such embodiments, the trapping chamber can incorporate a gas trapping filter or membrane to inhibit downstream flow of gas/air.


The fluid infusion device 102 may be provided in any desired configuration or platform. In accordance with one non-limiting embodiment, the fluid infusion device is realized as a portable unit that can be carried or worn by the patient. In this regard, FIG. 2 is a plan view of an exemplary embodiment of a fluid delivery system 200 that includes a portable fluid infusion device 202 and a fluid conduit assembly that takes the form of an infusion set component 204. For this particular embodiment, the infusion set component 204 can be coupled to the fluid infusion device 202 as depicted in FIG. 2. The fluid infusion device 202 accommodates a fluid reservoir (hidden from view in FIG. 2) for the medication fluid to be delivered to the user.


The illustrated embodiment of the infusion set component 204 includes, without limitation: a tube 210; an infusion unit 212 coupled to the distal end of the tube 210; and a connector assembly 214 coupled to the proximal end of the tube 210. The fluid infusion device 202 is designed to be carried or worn by the patient, and the infusion set component 204 terminates at the infusion unit 212 such that the fluid infusion device 202 can deliver fluid to the body of the patient via the tube 210. The fluid infusion device 202 may leverage a number of conventional features, components, elements, and characteristics of existing fluid infusion devices. For example, the fluid infusion device 202 may incorporate some of the features, components, elements, and/or characteristics described in U.S. Pat. Nos. 6,485,465 and 7,621,893, the relevant content of which is incorporated by reference herein.


The infusion set component 204 defines a fluid flow path that fluidly couples the fluid reservoir to the infusion unit 212. The connector assembly 214 mates with and couples to the neck region of the fluid reservoir, establishing the fluid path from the fluid reservoir to the tube 210. The connector assembly 214 (with the fluid reservoir coupled thereto) is coupled to the housing of the fluid infusion device 202 to seal and secure the fluid reservoir inside the housing. Thereafter, actuation of the fluid infusion device 202 causes the medication fluid to be expelled from the fluid reservoir, through the infusion set component 204, and into the body of the patient via the infusion unit 212 at the distal end of the tube 210. Accordingly, when the connector assembly 214 is installed as depicted in FIG. 2, the tube 210 extends from the fluid infusion device 202 to the infusion unit 212, which in turn provides a fluid pathway to the body of the patient. For the illustrated embodiment, the connector assembly 214 is realized as a removable reservoir cap (or fitting) that is suitably sized and configured to accommodate replacement of fluid reservoirs (which are typically disposable) as needed.



FIG. 3 is a perspective view of another exemplary embodiment of a fluid delivery system 300 that includes a fluid infusion device 302 designed to be affixed to the skin of the user. The fluid infusion device 302 includes two primary components that are removably coupled to each other: a durable housing 304; and a base plate 306. The fluid infusion device 302 also includes or cooperates with a removable/replaceable fluid reservoir (which is hidden from view in FIG. 3). For this particular embodiment, the fluid reservoir mates with, and is received by, the durable housing 304. In alternate embodiments, the fluid reservoir mates with, and is received by, the base plate 306.


The base plate 306 is designed to be temporarily adhered to the skin of the patient using, for example, an adhesive layer of material. After the base plate is affixed to the skin of the patient, a suitably configured insertion device or apparatus may be used to insert a fluid delivery needle or cannula 308 into the body of the patient. The cannula 308 functions as one part of the fluid delivery flow path associated with the fluid infusion device 302. In this regard, the cannula 308 and/or other structure in fluid communication with the cannula 308 may be considered to be one implementation of the fluid conduit assembly 104 shown in FIG. 1 (or a portion thereof).



FIG. 3 depicts the durable housing 304 and the base plate 306 coupled together. For this particular embodiment, the durable housing 304 contains, among other components, a drive motor, a battery, a threaded drive shaft for the fluid reservoir, one or more integrated circuit chips and/or other electronic devices (not shown). The durable housing 304 and the base plate 306 are cooperatively configured to accommodate removable coupling of the durable housing 304 to the base plate 306. The removable nature of the durable housing 304 enables the patient to replace the fluid reservoir as needed.


The fluid delivery systems 200, 300 described here are merely two exemplary embodiments that can include a fluid conduit assembly outfitted with a trapping chamber of the type described in more detail below. More specifically, the fluid delivery systems 200, 300 can manage the presence of gas/air in the medication fluid by way of a gas-venting trapping chamber, which can be incorporated into a fluid conduit assembly of the fluid delivery system. In this regard, FIG. 4 is a simplified block diagram representation of an embodiment of a trapping chamber 400 suitable for use in a fluid conduit assembly (such as the fluid conduit assembly 104, the infusion set component 204, a connector, an integrated feature of a fluid infusion device, a fluid reservoir, or the like). The trapping chamber 400 includes or defines an interior volume 402 that receives fluid, such as a medication fluid intended for delivery to the body of a patient. The trapping chamber 400 includes or cooperates with an inlet 404, which is in fluid communication with the interior volume 402. The inlet 404 may be implemented as part of the fluid conduit assembly, as part of the fluid delivery system, or the like. Fluid is provided from a fluid source (not shown), through the inlet 404, and into the interior volume 402 of the trapping chamber 400.


Ideally, medication fluid that enters the trapping chamber 400 should be free of bubbles, air, and other gas components. In practice, however, the liquid component of the medication fluid may contain some micro bubbles or trace amounts of gas. The trapping chamber 400 serves as a “staging area” for the received fluid during a fluid delivery operation. The trapping chamber 400 includes or cooperates with a liquid outlet arrangement 406 that facilitates flow of liquid out of the trapping chamber 400, and a gas outlet arrangement 408 that facilitates flow of gas out of the trapping chamber 400. More specifically, the liquid outlet arrangement 406 is suitably configured to accommodate flow of liquid from the interior volume 402 while inhibiting flow of gas from the interior volume 402. Conversely, the gas outlet arrangement 408 is suitably configured to accommodate flow of gas from the interior volume 402 while inhibiting flow of liquid from the interior volume 402. Although not depicted in FIG. 4, the gas outlet arrangement 408 can be implemented as a vent to allow gas to escape from the trapping chamber 400, and the liquid outlet arrangement 406 can be fluidly coupled to a fluid delivery conduit, a length of tubing, or the like. Thus, the liquid outlet arrangement 406 allows liquid to flow while blocking gas/air, and the gas outlet arrangement 408 allows gas to flow while blocking liquid.


The trapping chamber 400 that is schematically depicted in FIG. 4 can be implemented and realized in a variety of different ways. In some embodiments, the trapping chamber 400 is integrally formed in a reservoir cap of a fluid infusion device (see, for example, the connector assembly 214 shown in FIG. 2). In certain embodiments, the trapping chamber 400 is integrally formed in a fluid connector (such as a two-part detachable locking connector, a LUER LOK connector, or the like). In other embodiments, the trapping chamber 400 can be implemented in a fitting or a transfer guard that is utilized to transfer medication fluid (e.g., insulin) from a vial to a fluid reservoir of a fluid infusion device. Similarly, the trapping chamber 400 can be integrated into an automatic filling station that is operated to fill a fluid reservoir or an infusion device with the desired fluid. These and other implementations and embodiments are contemplated by this disclosure.



FIG. 5 is a perspective view of a fluid conduit assembly that is realized as a connector assembly or a reservoir cap 500 for a fluid reservoir. In this regard, the reservoir cap 500 is generally configured as described above for the connector assembly 214 shown in FIG. 2. Accordingly, the reservoir cap 500 may be provided as component of a disposable infusion set.


The illustrated embodiment of the reservoir cap 500 generally includes, without limitation: a body section 502; a flow path defined in the body section; a length of tubing 504 extending from the body section 502; and a trapping chamber (hidden from view). FIG. 5 depicts the body section 502 as two sections: a lower body section 502a; and an upper body section 502b. The trapping chamber can be integrally formed in the lower body section 502a.


The lower body section 502b is suitably configured to receive a fluid reservoir, e.g., by a threaded engagement, a snap fit, tabs, or the like. The tubing 504 is physically and fluidly coupled to the upper body section 502b such that the tubing 504 is in fluid communication with the flow path. This allows the tubing 504 to carry fluid from the body section 502 during a fluid delivery operation. The flow path, much of which is hidden from view in FIG. 5, may be defined by: a hollow needle that penetrates a septum of the fluid reservoir; an internal space, chamber, or conduit of the lower body section 502a, which is upstream of the trapping chamber; and an internal space, chamber, or conduit of the upper body section 502b, which is downstream of the trapping chamber. The flow path continues into the tubing 504, which is connected to the upper body section 502b.


The trapping chamber resides within the body section 502 such that it is positioned in the flow path of the medication fluid. During a fluid delivery operation, the medication fluid is forced out of the fluid reservoir and into the hollow needle (not shown in FIG. 5). The distal end of the hollow needle terminates at a location that is upstream of the trapping chamber. This positioning ensures that the medication fluid can be provided to the trapping chamber before it exits the reservoir cap 500.



FIG. 6 is a cross-sectional view of a portion of a fluid conduit assembly 900 having a trapping chamber 902 formed therein. This particular embodiment of the fluid conduit assembly 900 forms a part of a reservoir cap of a fluid infusion device, such as the reservoir cap 500 shown in FIG. 5. For simplicity and ease of illustration, however, surrounding structure and features of the reservoir cap are not shown or described here. Referring to FIG. 5, the trapping chamber 902 can be integrally formed in the body section 502 and in the fluid flow path. For example, the trapping chamber 902 can be located within the interior space that is generally defined by the lower body section 502a (this interior space is hidden from view in FIG. 5).


The exemplary embodiment of the fluid conduit assembly 900 generally includes, without limitation: the trapping chamber 902; an inlet 904 in fluid communication with an interior volume 906 of the trapping chamber 902; a hollow needle 908 coupled to the inlet 904; a liquid outlet arrangement 910 for the trapping chamber 902; a gas outlet arrangement 912 for the trapping chamber 902; and a length of hollow tubing 914 that serves as a fluid delivery conduit. During a fluid delivery operation, such as an insulin delivery operation of an insulin infusion pump, the desired fluid (e.g., insulin medication fluid) is dispensed from a fluid source such as a fluid reservoir. The hollow needle 908 is compatible with the fluid delivery source and the host fluid infusion system. The dispensed fluid enters the interior volume 906 by way of the hollow needle 908, which is in fluid communication with the fluid source. The liquid outlet arrangement 910 allows liquid to flow from the interior volume 906 to the hollow tubing 914, while inhibiting or preventing the flow of gas from the interior volume 906 to the hollow tubing 914. The gas outlet arrangement 912 allows gas to exit the interior volume 906, while inhibiting or preventing the flow of liquid from the interior volume 906.


The illustrated embodiment of the liquid outlet arrangement 910 includes, without limitation: at least one delivery hole 920 formed in a wall 922 of the trapping chamber 902; and at least one membrane 924 (also referred to here as the first membrane 924) covering or blocking at least a portion of the at least one delivery hole 920. For simplicity, FIG. 6 depicts only one delivery hole 920, which is formed in an upper wall 922 of the trapping chamber 902. In certain embodiments, the first membrane 924 completely covers or blocks the at least one delivery hole 920, as schematically depicted in FIG. 6. In practice, the first membrane 924 can be realized as a small disc or patch of material that is affixed or otherwise incorporated into the wall 922 as needed. It should be appreciated that the first membrane 924 can be located upstream of the delivery hole 920 (as shown), located downstream of the delivery hole 920, or positioned within the space defined by the delivery hole 920. Furthermore, more than one membrane 924 can be utilized within the defined fluid flow path if redundancy is desired.


The first membrane 924 exhibits hydrophilic properties, such that liquid can easily pass through the first membrane 924. Moreover, the properties of the first membrane 924 inhibit or prevent the flow of gas through the first membrane 924. Thus, the first membrane 924 is fabricated from a material (or materials) that is partially or predominantly hydrophilic. The hydrophilic characteristic of the first membrane 924 facilitates the flow of liquid medication fluid from the interior volume 906 to the hollow tubing 914, which is in fluid communication with the liquid outlet arrangement 910.


The first membrane 924 is formed from a suitable material, composition, or element such that the medication fluid can easily pass through the first membrane during fluid delivery operations. The first membrane 924 can be formed from a hydrophilic, semi-hydrophilic, partially hydrophilic, or predominantly hydrophilic material. Although a truly hydrophilic material may be ideal, the material used for the first membrane 924 can be partially or predominantly hydrophilic while exhibiting some amount of hydrophobicity. Non-limiting examples of suitable materials for the first membrane 924 include: polyacrylate; polyurethane; nylon; cellulose acetate; polyvinyl alcohol; polyethelene foam; polyvinyl acetate; polyester fiber felt; polyester (PET); polysulfone; polyethyl sulfone; collagen; polycaprolactone; or the like. It should be appreciated that the material or materials used to fabricate the first membrane 924 can be treated to enhance the hydrophilic characteristics if so desired.


The illustrated embodiment of the gas outlet arrangement 912 includes, without limitation: at least one vent hole 930 formed in the wall 922 of the trapping chamber 902; and at least one membrane 934 (also referred to here as the second membrane 934) covering or blocking at least a portion of the at least one vent hole 930. The cross-sectional view of FIG. 6 shows only two vent holes 930, however, the illustrated embodiment actually includes four vent holes 930 (see FIG. 7). In certain embodiments, the second membrane 934 completely covers or blocks the vent holes 930, as schematically depicted in FIG. 6. In practice, the second membrane 934 can be realized as individual pieces of material or as a unitary patch of material that is shaped and sized in accordance with the configuration of the vent holes 930. As described above for the first membrane 924, the material used for the second membrane 934 can be affixed or otherwise incorporated into the wall 922 as needed. It should be appreciated that the second membrane 934 can be located upstream of the vent holes 930 (as shown), located downstream of the vent holes 930, or positioned within the space defined by the vent holes 930. Furthermore, more than one second membrane 934 can be utilized within the defined fluid flow path if so desired.


The second membrane 934 exhibits hydrophobic properties, such that gas can easily pass through the second membrane 934. Moreover, the properties of the second membrane 934 inhibit or prevent the flow of liquid through the second membrane 934. Thus, the second membrane 934 is fabricated from a material (or materials) that is partially or predominantly hydrophobic. Indeed, the second membrane 934 can be fabricated using any suitable material or composition, including, without limitation: polytetrafluoroethylene (PTFE); fluoropolymers; glass fiber; treated or coated materials; or the like. The hydrophobic characteristic of the second membrane 934 facilitates the venting of gas/air from the interior volume 906 of the trapping chamber 902. In this regard, the vent holes 930 are preferably arranged and configured to exit into external airspace surrounding the trapping chamber 902. In other words, the vent holes 930 terminate at a location that is at ambient temperature and pressure.


In certain embodiments where the trapping chamber 902 is integrated into a reservoir cap of the type utilized with an insulin infusion pump, the hollow needle 908 receives insulin during a delivery operation that advances a piston or plunger of an insulin reservoir. In such an implementation, the interior volume 906 of the trapping chamber 902 can be within the range of about 1.0 microliters to about 500 microliters, although the actual volume may fall outside of this range in some embodiments. During a typical insulin delivery operation, the pressure within the interior volume 906 of the trapping chamber 902 can be within the range of about 1.0 psi to about 30 psi, although the actual pressure may fall outside of this range in some embodiments. The fluid pressure inside the trapping chamber 902 is sufficient to force the liquid insulin through the first membrane 924, and is sufficient to vent air or other gas components through the second membrane 934 as needed.



FIG. 7 is a top view of certain features of the fluid conduit assembly 900. For ease of illustration, FIG. 7 represents some features in cross-section and some features in phantom. Moreover, the scale and proportions shown in FIG. 7 may not be consistent with that shown in FIG. 6; the features are exaggerated in FIG. 7 for clarity. The trapping chamber 902 is shown in cross-section to illustrate the arrangement and locations of the vent holes 930, the delivery hole 920, the first membrane 924, and the second membrane 934. As shown in FIG. 7, the first membrane 924 can be realized as a round disc of material that covers the delivery hole 920 without interfering with the second membrane 934 or any of the vent holes 930.


The illustrated embodiment includes four vent holes 930 formed in a circular pattern around the delivery hole 920. It should be appreciated that other venting configurations and arrangements can be utilized in lieu of that shown in FIG. 7. The circular pattern of vent holes 930 can be covered with a single ring-shaped second membrane 934. In this regard, the second membrane 934 completely covers each vent hole 930 in a way that does not interfere with the first membrane 924 or the delivery hole 920. Accordingly, air is allowed to escape from any of the vent holes 930 (via the second membrane 934), but the first membrane 924 inhibits or prevents air from traveling downstream.


As explained above, a trapping chamber can be incorporated into a reservoir cap of an infusion pump. Referring to FIG. 5 and FIG. 2, the reservoir cap receives a fluid reservoir and also seals the fluid reservoir inside the housing (the main body) of the fluid infusion device 202. More specifically, the reservoir cap seals the fluid reservoir inside a chamber or cavity of the fluid infusion device 202, and the chamber can be isolated from other sections of the fluid infusion device 202. In certain embodiments, the reservoir cap includes one or more pressure vents formed therein to equalize pressure inside the reservoir chamber of the fluid infusion device 202. Pressure equalization is desirable to ensure that the piston of the fluid reservoir does not move in response to changes in atmospheric pressure, which may be caused by altitude changes.


In addition to the trapping chamber and venting arrangement described above, a reservoir cap may also include pressure vent holes formed therein for purposes of equalizing pressure inside the reservoir chamber. In certain embodiments, the pressure vent holes are formed in the wall 922 depicted in FIG. 6, which may correspond to a top portion of the reservoir cap (see FIG. 5). In such embodiments, the pressure vent holes are external to the trapping chamber. In other words, the pressure vent holes are not in fluid communication with the interior volume of the trapping chamber. Instead, the pressure vent holes serve as a gas conduit from the volume inside the reservoir cavity that surrounds the exterior surface of the fluid reservoir.


Notably, the hydrophobic membrane 934 (see FIG. 6 and FIG. 7) that covers the vent holes 930 can be extended or otherwise configured to also cover the pressure vent holes. Accordingly, the membrane 934 facilitates equalization of air pressure inside the reservoir cavity while also inhibiting the ingress of fluid or contaminants into the reservoir cavity. Although it is preferable to use the same membrane 934 to cover the pressure vent holes and the vent holes 930, it should be understood that distinct hydrophobic membranes may be used if so desired.


While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application.

Claims
  • 1. A fluid conduit assembly for delivery of a medication fluid, the fluid conduit assembly comprising: a reservoir cap comprising a lower body section configured to receive and couple to a fluid reservoir, and configured to couple to a housing of a fluid infusion device to seal and secure the fluid reservoir inside the housing;a trapping chamber integrally formed in the lower body section of the reservoir cap, the trapping chamber comprising an upper wall, a delivery hole formed in the upper wall, a plurality of vent holes formed in the upper wall and arranged around the delivery hole, and an interior volume to receive the medication fluid from the fluid reservoir;an inlet in fluid communication with the interior volume, the inlet formed in a lower wall of the trapping chamber, the lower wall opposing the upper wall of the trapping chamber;a first outlet arrangement for the trapping chamber, the first outlet arrangement accommodating flow of liquid from the interior volume and inhibiting flow of gas from the interior volume, the first outlet arrangement comprising a first membrane completely covering the delivery hole, the first membrane having hydrophilic properties;a length of hollow tubing in fluid communication with the first outlet arrangement by way of the delivery hole formed in the upper wall; anda second outlet arrangement for the trapping chamber, the second outlet arrangement accommodating flow of gas from the interior volume and inhibiting flow of liquid from the interior volume, the second outlet arrangement comprising a second membrane completely covering the plurality of vent holes, the second membrane having hydrophobic properties;wherein the first membrane covers the delivery hole without interfering with the second membrane and without interfering with any of the plurality of vent holes; andwherein the second membrane comprises a single ring-shaped membrane that surrounds the first membrane without interfering with the first membrane and without interfering with the delivery hole.
  • 2. The fluid conduit assembly of claim 1, further comprising a hollow needle coupled to the inlet, wherein the medication fluid enters the interior volume of the trapping chamber via the hollow needle during a fluid delivery operation.
  • 3. The fluid conduit assembly of claim 1, wherein the vent hole exits into external airspace surrounding the trapping chamber.
  • 4. A fluid delivery system comprising: a fluid infusion pump; anda fluid conduit assembly coupled to the fluid infusion pump, the fluid conduit assembly comprising: a reservoir cap comprising a lower body section configured to receive and couple to a fluid reservoir, and configured to couple to a housing of the fluid infusion pump to seal and secure the fluid reservoir inside the housing;a trapping chamber integrally formed in the lower body section of the reservoir cap, the trapping chamber having an upper wall, a delivery hole formed in the upper wall, a plurality of vent holes formed in the upper wall and arranged around the delivery hole, and an interior volume to receive fluid from the fluid reservoir;an inlet in fluid communication with the interior volume, the inlet formed in a lower wall of the trapping chamber, the lower wall opposing the upper wall of the trapping chamber;a liquid outlet arrangement that allows liquid to flow from the interior volume to a fluid delivery conduit in fluid communication with the delivery hole, while inhibiting flow of gas from the interior volume to the fluid delivery conduit, the liquid outlet arrangement comprising a first membrane completely covering the delivery hole, the first membrane having hydrophilic properties; anda gas outlet arrangement that allows gas to exit the interior volume while inhibiting flow of liquid from the interior volume, the gas outlet arrangement comprising a second membrane completely covering the plurality of vent holes, the second membrane having hydrophobic properties;wherein the first membrane covers the delivery hole without interfering with the second membrane and without interfering with any of the plurality of vent holes; andwherein the second membrane comprises a single ring-shaped membrane that surrounds the first membrane without interfering with the first membrane and without interfering with the delivery hole.
US Referenced Citations (244)
Number Name Date Kind
3631847 Hobbs, II Jan 1972 A
3803810 Rosenberg Apr 1974 A
4009715 Forberg Mar 1977 A
4190426 Ruschke Feb 1980 A
4200095 Reti Apr 1980 A
4212738 Henne Jul 1980 A
4270532 Franetzki et al. Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4373527 Fischell Feb 1983 A
4395259 Prestele et al. Jul 1983 A
4433072 Pusineri et al. Feb 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4494950 Fischell Jan 1985 A
4542532 McQuilkin Sep 1985 A
4550731 Batina et al. Nov 1985 A
4559037 Franetzki et al. Dec 1985 A
4562751 Nason et al. Jan 1986 A
4642098 Lundquist Feb 1987 A
4671288 Gough Jun 1987 A
4678408 Nason et al. Jul 1987 A
4685903 Cable et al. Aug 1987 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4781798 Gough Nov 1988 A
4803625 Fu et al. Feb 1989 A
4809697 Causey, III et al. Mar 1989 A
4826810 Aoki May 1989 A
4871351 Feingold Oct 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
5003298 Havel Mar 1991 A
5011468 Lundquist et al. Apr 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5078683 Sancoff et al. Jan 1992 A
5080653 Voss et al. Jan 1992 A
5097122 Colman et al. Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5101814 Palti Apr 1992 A
5108819 Heller et al. Apr 1992 A
5153827 Coutre et al. Oct 1992 A
5165407 Wilson et al. Nov 1992 A
5247434 Peterson et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5284140 Allen et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5307263 Brown Apr 1994 A
5317506 Coutre et al. May 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5338157 Blomquist Aug 1994 A
5339821 Fujimoto Aug 1994 A
5341291 Roizen et al. Aug 1994 A
5350411 Ryan et al. Sep 1994 A
5356786 Heller et al. Oct 1994 A
5357427 Langen et al. Oct 1994 A
5362406 Gsell Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5403700 Heller et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5439587 Stankowski Aug 1995 A
5482473 Lord et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5497772 Schulman et al. Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5522769 DeGuiseppi Jun 1996 A
5543326 Heller et al. Aug 1996 A
5569186 Lord et al. Oct 1996 A
5569187 Kaiser Oct 1996 A
5573506 Vasko Nov 1996 A
5575279 Beplate Nov 1996 A
5582593 Hultman Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593390 Castellano et al. Jan 1997 A
5593852 Heller et al. Jan 1997 A
5594638 Iliff Jan 1997 A
5609060 Dent Mar 1997 A
5626144 Tacklind et al. May 1997 A
5630710 Tune et al. May 1997 A
5643212 Coutre et al. Jul 1997 A
5660163 Schulman et al. Aug 1997 A
5660176 Iliff Aug 1997 A
5665065 Colman et al. Sep 1997 A
5665222 Heller et al. Sep 1997 A
5685844 Marttila Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5704366 Tacklind et al. Jan 1998 A
5750926 Schulman et al. May 1998 A
5754111 Garcia May 1998 A
5764159 Neftel Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5779665 Mastrototaro et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5791344 Schulman et al. Aug 1998 A
5800420 Gross et al. Sep 1998 A
5807336 Russo et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5832448 Brown Nov 1998 A
5840020 Heinonen et al. Nov 1998 A
5861018 Feierbach et al. Jan 1999 A
5868669 Iliff Feb 1999 A
5871465 Vasko Feb 1999 A
5879163 Brown et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5904708 Goedeke May 1999 A
5913310 Brown Jun 1999 A
5917346 Gord Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5940801 Brown Aug 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5965380 Heller et al. Oct 1999 A
5972199 Heller et al. Oct 1999 A
5978236 Faberman et al. Nov 1999 A
5997476 Brown Dec 1999 A
5999848 Gord et al. Dec 1999 A
5999849 Gord et al. Dec 1999 A
6009339 Bentsen et al. Dec 1999 A
6032119 Brown et al. Feb 2000 A
6043437 Schulman et al. Mar 2000 A
6081736 Colvin et al. Jun 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6101478 Brown Aug 2000 A
6103033 Say et al. Aug 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6134461 Say et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6183412 Benkowski et al. Feb 2001 B1
6246992 Brown Jun 2001 B1
6259937 Schulman et al. Jul 2001 B1
6329161 Heller et al. Dec 2001 B1
6408330 DeLaHuerga Jun 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6472122 Schulman et al. Oct 2002 B1
6484045 Holker et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6503381 Gotoh et al. Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6544173 West et al. Apr 2003 B2
6553263 Meadows et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560741 Gerety et al. May 2003 B1
6565509 Say et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6585695 Adair Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6592745 Feldman et al. Jul 2003 B1
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607658 Heller et al. Aug 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618934 Feldman et al. Sep 2003 B1
6623501 Heller et al. Sep 2003 B2
6641533 Causey, III et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6659980 Moberg et al. Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6676816 Mao et al. Jan 2004 B2
6689265 Heller et al. Feb 2004 B2
6728576 Thompson et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6747556 Medema et al. Jun 2004 B2
6749740 Liamos et al. Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6809653 Mann et al. Oct 2004 B1
6817990 Yap et al. Nov 2004 B2
6881551 Heller et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6916159 Rush et al. Jul 2005 B2
6932584 Gray et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6942518 Liamos et al. Sep 2005 B2
7153263 Carter et al. Dec 2006 B2
7153289 Vasko Dec 2006 B2
7396330 Banet et al. Jul 2008 B2
7621893 Moberg et al. Nov 2009 B2
20010044731 Coffman et al. Nov 2001 A1
20020013518 West et al. Jan 2002 A1
20020055857 Mault et al. May 2002 A1
20020077598 Yap et al. Jun 2002 A1
20020082665 Haller et al. Jun 2002 A1
20020137997 Mastrototaro et al. Sep 2002 A1
20020161288 Shin et al. Oct 2002 A1
20030060765 Campbell et al. Mar 2003 A1
20030078560 Miller et al. Apr 2003 A1
20030088166 Say et al. May 2003 A1
20030144581 Conn et al. Jul 2003 A1
20030152823 Heller Aug 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030188427 Say et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030220552 Reghabi et al. Nov 2003 A1
20040061232 Shah et al. Apr 2004 A1
20040061234 Shah et al. Apr 2004 A1
20040064133 Miller et al. Apr 2004 A1
20040064156 Shah et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040074785 Holker et al. Apr 2004 A1
20040093167 Braig et al. May 2004 A1
20040097796 Berman et al. May 2004 A1
20040102683 Khanuja et al. May 2004 A1
20040111017 Say et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040263354 Mann et al. Dec 2004 A1
20050038331 Silaski et al. Feb 2005 A1
20050038680 McMahon et al. Feb 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20060229694 Schulman et al. Oct 2006 A1
20060238333 Welch et al. Oct 2006 A1
20060293571 Bao et al. Dec 2006 A1
20070088521 Shmueli et al. Apr 2007 A1
20070135866 Baker et al. Jun 2007 A1
20080154503 Wittenber et al. Jun 2008 A1
20090081951 Erdmann et al. Mar 2009 A1
20090082635 Baldus et al. Mar 2009 A1
20120172800 Dudar et al. Jul 2012 A1
20130103002 Fruenlund Apr 2013 A1
Foreign Referenced Citations (33)
Number Date Country
4329229 Mar 1995 DE
0057001 Aug 1982 EP
0319268 Nov 1988 EP
0806738 Nov 1997 EP
0880936 Dec 1998 EP
1338295 Aug 2003 EP
1442761 Aug 2004 EP
1631036 Mar 2006 EP
2500051 Sep 2012 EP
1401382 Jul 1975 GB
2218831 Nov 1989 GB
WO 9506506 Mar 1995 WO
WO 9506506 Mar 1995 WO
WO 9620745 Jul 1996 WO
WO 9636389 Nov 1996 WO
WO 9637246 Nov 1996 WO
WO 9721456 Jun 1997 WO
WO 9820439 May 1998 WO
WO 9824358 Jun 1998 WO
WO 9842407 Oct 1998 WO
WO 9849659 Nov 1998 WO
WO 9859487 Dec 1998 WO
WO 9908183 Feb 1999 WO
WO 9910801 Mar 1999 WO
WO 9918532 Apr 1999 WO
WO 9922236 May 1999 WO
WO 0010628 Mar 2000 WO
WO 0019887 Apr 2000 WO
WO 0048112 Aug 2000 WO
WO 02058537 Aug 2002 WO
WO 03001329 Jan 2003 WO
WO 03094090 Nov 2003 WO
WO 2005065538 Jul 2005 WO
Non-Patent Literature Citations (92)
Entry
PCT Search Report (PCT/US02/03299), dated Oct. 31, 2002, Medtronic Minimed, Inc.
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy.
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327.
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition.
Brackenridge B P (1992). Carbohydrate Gram Counting a Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28.
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc.
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138.
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283.
Kulkarni K et al. (1999). Carbohydrate Counting a Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc.
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142.
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38.
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company.
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed•Technologies.
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60.
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed•Technologies.
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78.
Disetronic My Choice™ D-TRON™ Insulin Pump Reference Manual. (no date).
Disetronic H-TRON® plus Quick Start Manual. (no date).
Disetronic My Choice H-TRONplus Insulin Pump Reference Manual. (no date).
Disetronic H-TRON®plus Reference Manual. (no date).
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506—pic.htm.
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm.
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq—pract.htm.
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm.
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide.
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages.
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide.
(MiniMed International, 1998). MiniMed 507C Insulin Pump for those who appreciate the difference.
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy.
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life.
(MiniMed, 2000). MiniMed® 508 User's Guide.
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator.
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy.
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management.
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence.
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version.
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584.
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696.
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197.
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473.
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540.
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70.
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241.
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54.
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357.
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263.
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975.
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389.
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134.
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179.
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714.
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468.
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40.
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765.
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52.
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36.
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165.
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144.
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991.
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532.
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16.
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484.
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077.
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172.
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358.
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103.
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663.
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220.
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406.
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9.
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292.
Shichiri, Motoaki, et al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202.
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313.
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275.
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301.
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131.
Shichiri, Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370.
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041.
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942.
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40.
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307.
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091.
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739.
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562.
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233.
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847.
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98.
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142.
Related Publications (1)
Number Date Country
20160144102 A1 May 2016 US